β-blockers and statins: exploring the potential off-label applications in breast, colorectal, prostate, and lung cancers

Despite advances in cancer treatment, current cancer incidence and prevalence still demand multimodal treatments to enhance survival and clinical outcomes. Drugs used in cardiology, such as β-blockers and statins have gained attention for their potential roles in oncology. This review focused on the...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2024-11, Vol.15, p.1423502
Main Authors: Braga, Pedro Gabriel Senger, Vieira, Janaína da Silva, Gurgel, Aline Rachel Bezerra, Brum, Patricia Chakur
Format: Article
Language:English
Subjects:
drug repositioning
Pharmacology
solid cancer
statin
survival
β-blockers
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite advances in cancer treatment, current cancer incidence and prevalence still demand multimodal treatments to enhance survival and clinical outcomes. Drugs used in cardiology, such as β-blockers and statins have gained attention for their potential roles in oncology. This review focused on their possible complementary use in solid tumors, including breast, colorectal, lung, and prostate cancers. The involvement of the autonomic nervous system in promoting tumor growth can be disrupted by β-blockers, potentially hindering cancer progression. Statins, known for their pleiotropic effects, may also inhibit cancer growth by reducing cholesterol availability, a key factor in cell proliferation. We will provide an update on the impact of these therapies on cancer treatment and surveillance, discuss the underlying mechanisms, and explore their effects on the heart, contributing to the growing field of cardio-oncology.
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2024.1423502